PMID- 28469716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1817-1737 (Print)
IS  - 1998-3557 (Electronic)
IS  - 1998-3557 (Linking)
VI  - 12
IP  - 2
DP  - 2017 Apr-Jun
TI  - Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PG  - 74-82
LID - 10.4103/atm.ATM_231_16 [doi]
AB  - Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often 
      occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a 
      hypersensitivity response to the allergens of the fungus Aspergillus fumigatus. 
      In patients with CF, growth of A. fumigatus hyphae within the bronchial lumen 
      triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that 
      results in airway inflammation, bronchospasm, and bronchiectasis. In most 
      published studies, the prevalence of ABPA is about 8.9% in patients with CF. 
      Since the clinical features of this condition overlap significantly with that of 
      CF, ABPA is challenging to diagnose and remains underdiagnosed in many patients. 
      Diagnosis of ABPA in CF patients should be sought in those with evidence of 
      clinical and radiologic deterioration that is not attributable to another 
      etiology, a markedly elevated total serum IgE level (while off steroid therapy) 
      and evidence of A. fumigatus sensitization. Management of ABPA involves the use 
      of systemic steroids to reduce inflammation and modulate the immune response. In 
      patients who do not respond to steroids or cannot tolerate them, antifungal 
      agents should be used to reduce the burden of A. fumigatus allergens. Recent 
      studies suggest that omalizumab may be an effective option to reduce the 
      frequency of ABPA exacerbations in patients with CF. Further randomized 
      controlled trials are needed to better establish the efficacy of omalizumab in 
      managing patients with CF and ABPA.
FAU - Janahi, Ibrahim Ahmed
AU  - Janahi IA
AD  - Department of Clinical Pediatrics, Weill Cornell Medical College-Qtar, Doha, 
      Qatar.
AD  - Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.
FAU - Rehman, Abdul
AU  - Rehman A
AD  - Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
FAU - Al-Naimi, Amal Rashid
AU  - Al-Naimi AR
AD  - Department of Clinical Pediatrics, Weill Cornell Medical College-Qtar, Doha, 
      Qatar.
AD  - Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Ann Thorac Med
JT  - Annals of thoracic medicine
JID - 101280721
PMC - PMC5399694
OTO - NOTNLM
OT  - Allergic bronchopulmonary aspergillosis
OT  - allergic fungal mycosis
OT  - cystic fibrosis
COIS- There are no conflicts of interest.
EDAT- 2017/05/05 06:00
MHDA- 2017/05/05 06:01
PMCR- 2017/04/01
CRDT- 2017/05/05 06:00
PHST- 2017/05/05 06:00 [entrez]
PHST- 2017/05/05 06:00 [pubmed]
PHST- 2017/05/05 06:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - ATM-12-74 [pii]
AID - 10.4103/atm.ATM_231_16 [doi]
PST - ppublish
SO  - Ann Thorac Med. 2017 Apr-Jun;12(2):74-82. doi: 10.4103/atm.ATM_231_16.